Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28058377 | 0.98 | LMNA (0.52) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL14363640 | 0.91 | LMNA (0.48) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL252338 | 0.83 | TDP1 (0.50) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL27537130 | 0.82 | TDP1 (0.55) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL7687990 | 0.82 | TDP1 (0.55) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL546820 | 0.80 | — | — | |
| SCHEMBL14668317 | 0.80 | — | — | |
| Mannitol SCHEMBL11105758 | 0.79 | LMNA (0.57) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| Sorbitol SCHEMBL247059 | 0.79 | LMNA (0.57) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL5573408 | 0.77 | TDP1 (0.55) | TDP1LMNAL3MBTL1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2048 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| CN-118325655-A | Cutting fluid additive for microcrystalline glass processing and preparation method and application thereof | 广州亦盛环保科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-111757731-B | Methods of using trisubstituted benzotriazole derivatives | 法国施维雅药厂 | 2024-06-25 | — | — | CN | disclosed |
| CN-116284043-B | Tricyclic compound and medical application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| US-11992549-B2 | Oil-in-water emulsion | WACKER CHEMIE AG (DE) | 2024-05-28 | — | — | US | disclosed |
| WO-2024102447-A1 | USES OF HYDROIMIDAZOPYRIDOPYRIMIDINONE DERIVATIVES FOR MANAGING ANEURYSMS OR OTHER VASCULAR CONDITIONS OR DISEASES | EMORY UNIVERSITY (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240148697-A1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES | SERVIER PHARMACEUTICALS LLC | 2024-05-09 | — | — | US | disclosed |
| CN-112457298-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050119318-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| US-20040248778-A1 | Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides | VISCUM AG (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003024447-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6486165-B2 | TREATING WITH AGONISTS AT KAPPA OPIOID RECEPTORS SUCH AS METHYL-4-(2-GLYCYL-4-(TRIFLUOROMETHYLPHENYL)ACETYL)-3-(R,S)-((1 -PYRROLIDINYL)-METHYL)-1-PIPERAZINECARBOXYLATE | ADOLOR CORPORATION | 2002-11-26 | — | — | US | disclosed |
| EP-0122348-B1 | INK COMPOSITION FOR WRITING INSTRUMENT | ADGER KOGYO CO., LTD. (JP) | 1989-03-01 | — | — | EP | disclosed |
| US-4509982-A | Ink composition for writing instruments | ADGER KOGYO CO., LTD. (JP) | 1985-04-09 | — | — | US | disclosed |
| EP-0122348-A2 | Ink composition for writing instrument | ADGER KOGYO CO., LTD. (JP) | 1984-10-24 | — | — | EP | disclosed |
| US-4192766-A | NONIONIC SURFACTANT, PROPELLANT | UNITED CHEMICAL CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |